摘要
目的:回顾性分析乳腺癌患者的乳腺影像报告和数据系统(Breast Imaging Reporting and Data System,BIRADS)超声征象,探讨无创的超声检查与乳腺癌分子分型生物学指标的相关性。方法:选取160例女性乳腺癌患者,均有完整的术前超声诊断资料和术后病理组织学和免疫组织化学检查结果,对肿瘤术前超声检查征象采用BI-RADS术语进行描述和评估分类,按免疫组织化学检查结果对肿瘤进行分子分型,对比分析肿瘤的超声BI-RADS征象与其分子分型的相关性。结果:各型乳腺癌中,Luminal A型和Luminal B型后方回声衰减所占比例最高,HER2过表达型癌组织边缘有毛刺征的比例最低、出现微钙化的比例最高,三阴性型肿块边缘光整、后方回声增强比例最高,差异均有统计学意义(P<0.05)。结论:乳腺癌的BI-RADS超声征象对判断其分子分型有一定诊断价值,了解乳腺癌各分子分型的典型超声征象,有助于超声医师更早、更准确地诊断乳腺癌,为临床医师制定治疗方案和评估肿瘤预后提供更有价值的影像学依据。
Objective:To retrospectively review the ultrasound signs of breast cancer based on the Breast Imaging Reporting and Data System(BI-RADS),and investigate their correlation to molecular typing of breast cancer.Methods:160 breast cancer patients with complete preoperative ultrasonic,postoperative histopathologic and immunohistochemical records were selected.According to BI-RADS(fifth version)issued by American College of Radiology,preoperative sonographic features of included cases were assessed and categorized.Breast cancers were categorized into different molecular types according to immunohistochemical results.The correlation between BI-RADS ultrasound signs of breast cancer and molecular typing of breast cancer was comparatively reviewed.Results:Luminal A and Luminal B breast cancers were the high-est in the proportion of posterior acoustic attenuation(P<0.05);HER2 over-expressed breast cancer was the lowest in the proportion of tumor with burrs on its margins(P<0.05),and its proportion of microcalcification was the highest(P<0.05);triple-negative breast cancer showed a highest proportion of well-defined margins and posterior acoustic enhancement(P<0.05).Conclusion:BI-RADS ultrasound signs of breast cancer is of certain diagnostic value in judging its molecular type.It will help sonographers diagnose breast cancer earlier and more accurately,and provide more valuable imaging evidence for clinicians in formulating treatment plans and evaluate tumor prognosis.
作者
周成香
刘健
苟博
胡静
黄蓉飞
Zhou Chengxiang;Liu Jian;Gou Bo;Hu Jing;Huang Rongfei(Department of Ultrasound,the First Affiliated Hospital of Chengdu Medical College&Clinical Medical College of Chengdu Medical College,Chengdu 610500,Sichuan,China;Department of Pathology,the First Affiliated Hospital of Chengdu Medical College&Clinical Medical College of Chengdu Medical College,Chengdu 610500,Sichuan,China)
出处
《肿瘤预防与治疗》
2020年第11期866-873,共8页
Journal of Cancer Control And Treatment
基金
四川省医学科研课题计划项目(编号:Q18005)。
